Citadel Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Citadel Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-66,300	Closed	-$7.12M	–	15642
2023 Q1	$7.12M	Sell	66,300 -232,900	-78%	-$26.8M	﹤0.01%	3262
2022 Q4	$32.9M	Buy	299,200 +247,900	+483%	+$16.1M	0.01%	1470
2022 Q3	$3.03M	Buy	51,300 +700	+1%	+$32K	﹤0.01%	4792
2022 Q2	$1.43M	Buy	+50,600	New	+$1.47M	﹤0.01%	6222

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Citadel Advisors's RXDX Position: Q2 2023 in Review

Citadel Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 47,146 shares — an estimated $5.06M sold.

Citadel Advisors first reported a position in RXDX in Q1 2021 and held it in 6 quarters. The position peaked at $18.3M in Q2 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Citadel Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 47,146 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.06M.
Citadel Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
Citadel Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $18.3M in Q2 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.